ASTRAZENECA DL-,25 SP.ADR
ASTRAZENECA DL-,25 SP.ADR/ US0463531089 /
ZEGA
2024. 06. 21. 16:12:49
|
Vált.
+1,000
|
Forgalom (db) |
Vétel16:49:14 |
Eladás16:49:14 |
Piaci kapitalizáció |
Osztalékh. |
P/E Ráta |
73,500EUR
|
+1,38%
|
- Forgalom: - |
74,000Vétel (db): 2 222 |
74,500Eladás (db): 2 500 |
228,19 mrd.EUR |
- |
- |
Cégbemutató
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Igazgatóság & Felügyelőbizottság
CEO |
Pascal Soriot |
Igazgatóság |
Aradhana Sarin, Pam Cheng, Ruud Dobber, Marc Dunoyer, David Fredrickson, Susan Galbraith, Menelas (Mene) Pangalos, Jeff Pott, Iskra Reic, Leon Wang, Sharon Barr |
Felügyelőbizottság |
Michel Demaré, Pascal Soriot, Aradhana Sarin, Philip Broadley, Euan Ashley, Deborah DiSanzo, Diana Layfield, Sheri McCoy, Tony Mok, Nazneen Rahman, Andreas Rummelt, Marcus Wallenberg |